August 17, 2017 8:32 PM ET

Biotechnology

Company Overview of Liquidia Technologies, Inc.

Company Overview

Liquidia Technologies, Inc., a nanotechnology company, designs, develops, and manufactures precisely engineered particles and films for various life and materials science applications. The company manufactures engineered particles using PRINT (Particle Replication In Non-Wetting Templates), a particle engineering and manufacturing technology. It applies its technology to develop products in pulmonary, ophthalmology, post-operative care, and vaccine areas, such as internal development of LIQ861 for inhaled and LIQ865 for pain relief, as well as a treatment for glaucoma. The company also licenses its PRINT particle technology and its cGMP manufacturing capabilities to support programs advanced...

419 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 2004

Phone:

919-328-4400

Fax:

919-328-4402

Key Executives for Liquidia Technologies, Inc.

Chief Executive Officer & Director
Age: 55
Co-Founder and Senior Scientist
Co-Founder
Chief Financial Officer
Compensation as of Fiscal Year 2017.

Liquidia Technologies, Inc. Key Developments

Liquidia Technologies Announces Positive Phase 1 Data for LIQ865, Sustained-Delivery Print® Formulation of Bupivacaine for Post-Surgical Pain Relief

Liquidia Technologies, Inc. announced initial data from its LIQ865 internal clinical development program, which is a PRINT® formulation for the sustained-delivery of free base bupivacaine for post-surgical pain relief. The phase 1 trial, marking the first evaluation of LIQ865 in humans, was a randomized, controlled, double-blind study evaluating the safety, pharmacokinetic profile and pharmacodynamic response of a single-ascending dose in healthy adult males. Topline data indicate that LIQ865 doses were well tolerated and the pharmacodynamic response was consistent with a local anesthetic effect lasting for three or more days. Liquidia is developing LIQ865 with the goal of providing at least three days of post-surgical pain relief with a single administration, potentially minimizing or avoiding the need for opioid analgesics. There are over 80 million inpatient and outpatient surgeries performed every year, with the majority of surgeries requiring opioids to treat moderate to severe post-operative pain. A minority of these individuals will become long-term users and have the potential for opioid misuse and addiction. The phase 1 clinical trial results for LIQ865 further validate the remarkably broad applicability of the PRINT technology across virtually any therapeutic area. This phase 1 randomized, controlled, double-blind study evaluated the safety and pharmacokinetics/pharmacodynamics of single ascending doses of LIQ865 injection in 28 healthy adult male volunteers. This was a single site study conducted in Copenhagen, Denmark under a Clinical Trial Authorisation and Independent Ethics Committee approval. Each trial participant received active drug in the medial aspect of one calf and control in the other calf.

Liquidia Technologies To Reportedly Go Public

Liquidia Technologies, Inc., which is backed by the Bill & Melinda Gates Foundation Asset Trust may reportedly come up with an Initial Public Offering in Singapore in 2017 at a valuation of SGD 300 million.

Liquidia Technologies, Inc. Appoints Arthur S. Kirsch as Director and Chairman of the Audit Committee

Liquidia Technologies, Inc. announced the appointment of Arthur S. Kirsch to its board of directors and named him Chairman of the audit committee. Mr. Kirsch is currently a Senior Advisor with GCA Global, LLC, and brings to Liquidia over 30 years of experience in investment banking and equity capital markets, as well as extensive knowledge of the healthcare and life sciences industries.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Liquidia Technologies, Inc., please visit www.liquidia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.